Lucid Diagnostics gains strategic VA partnership to deploy EsoGuard across veteran programs
Discover how Lucid Diagnostics is expanding EsoGuard adoption with a new U.S. Veterans Affairs contract for early cancer screening.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Guardant Health and Merck sign global deal to co-develop cancer companion diagnostics
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
Medical Devices & Diagnostics
What Pillar Biosciences’ China move means for decentralized oncology diagnostics
Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround
Medical Devices & Diagnostics
Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.